KRYSKrystal Biotech, Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 17838
Ticker: KRYS
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2017-09-20
Round lot: 40
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: KRYS

Detail

Enriched 2026-08-14 20:47

Market cap: $9,852,268,550.96
Shares outstanding (class): 29,598,836
Shares outstanding (weighted): 29,598,836
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees: 295
Location: PITTSBURGH, PA
Homepage: https://www.krystalbio.com
Description: Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Market cap and share counts drift.

Funds holding this security

185 funds · 187 positions · $2.24B reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
iShares Core S&P Small-Cap ETF iShares Trust	IJR	$400.40M	0.44%	1,550,015 NS	FIGI
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$214.57M	0.01%	830,630 NS	FIGI
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$194.32M	0.24%	752,244 NS	FIGI
VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS	VB	$156.69M	0.10%	606,580 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$156.45M	0.22%	605,659 NS	FIGI
VANGUARD SMALL-CAP GROWTH INDEX FUND VANGUARD INDEX FUNDS	VBK	$87.61M	0.23%	339,149 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$85.83M	1.15%	332,277 NS	FIGI
Hood River Small-Cap Growth Fund Manager Directed Portfolios	—	$85.19M	1.64%	329,780 NS	FIGI
First Trust NYSE Arca Biotechnology Index Fund First Trust Exchange-Traded Fund	FBT	$79.69M	3.51%	308,504 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$74.46M	0.09%	288,234 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$70.64M	0.65%	273,451 NS	FIGI
State Street(R) SPDR(R) Portfolio S&P 600(TM) S… SPDR SERIES TRUST	SPSM	$60.40M	0.44%	233,810 NS	FIGI
iShares S&P Small-Cap 600 Growth ETF iShares Trust	IJT	$57.52M	0.88%	222,667 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$52.22M	0.43%	202,167 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$48.81M	0.60%	188,966 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERKRYS
FIGI_COMPOSITEBBG00HDGRHH7
FIGI_SHARE_CLASSBBG00HDGRHJ5
CIK0001711279
ISINUS5011471027
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Biotechnology
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Krystal Biotech is a biopharmaceutical company developing gene therapies, fitting the biotechnology industry under healthcare.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.